Upload
helena-farmer
View
213
Download
0
Tags:
Embed Size (px)
Citation preview
Personalized Medicine: A topical analysis using Thomson Reuters data and analytics
MLA annual meetingMay, 2010
Ann Kushmerick,Manager, Research Evaluation and Bibliometric Data
2
What is personalized medicine?
Information about a patient's protein, gene or metabolite profile could be used to tailor medical care
Individual’s information is being used:
–to stratify disease status
–select from among different medications
–tailor dosages
–provide a specific therapy
–initiate a preventative measure
“A form of medicine that uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat disease.” -National Cancer Institute
U.S. to Compare Medical Treatments February 15, 2009 The $787 billion economic stimulus bill approved by Congress will, for the first time, provide substantial amounts of money for the federal government to compare the effectiveness of different treatments for the same illness.
- New York Times
3
UPDATE: Personalized Medicine Poised to Become Part of US Healthcare Reform Plan March 24, 2010The healthcare reform bill includes a section on comparative effectiveness research that creates the Patient-Centered Outcomes Research Institute. Seen as a victory for personalized medicine, the institute will study the utility of medical products in "various subpopulations," including groups differentiated by genetic and molecular subtypes.
- Genomeweb.com
How did we define personalized medicine for this presentation?
• individualized health
• prospective care
• molecular diagnostic test*
• pharmacogenetic test*
• protein expression profil*
• therapist/physician SAME tailored
4
• molecular profiling
• pharmacogenomic
• pharmacogenetic
• biomarker SAME gene
• treatment individualization
• personalized SAME therapy
Examples of keywords used:
What questions can Thomson Reuters data answer about personalized medicine?
• Who are the highly cited institutions and researchers in this field?
• What are the publication and citation trends?
• Who collaborates in this area?
• What countries have the most impact in personalized medicine?
• What are the key journal articles/patents/book chapters/conference proceedings on this topic?
5
Manage Manage Research Research OutputOutput
6
QualitySearch & Search & DiscoverDiscover
Write & Write & PublishPublish
Research CycleResearch CycleResearch CycleResearch Cycle
•Web of Science•BIOSIS Previews•BIOSIS Citation Index•Zoological Record•Derwent Innovations Index•INSPEC•CAB Abstracts and Global Health•MEDLINE
•EndNote •EndNote Web•Scholar One
•InCites•Journal Citation Reports•Custom data •Web Services
•Researcher ID•Thomson Pharma•Thomson Innovation
Thomson Reuters: Solutions for the entire research cycle
Evaluate Evaluate outcomesoutcomes
Thomson Reuters Web of Knowledge: a comprehensive, biomedical discovery tool
7
Web of Science
- 10,000 Journals, Natural and Social Sciences Coverage back to 1900
- 12,000 Conference Proceedings Annually
BIOSIS Previews and BIOSIS Citation Index
- 5,250 Journals
- Thousands of Meetings, Books, Patents Annually
MEDLINE
5,180 Journals
Who is funding personalized medicine research?
12
Number of papers by funding body acknowledged: Web of Science
BIOSIS Citation Index
13
A citation resource providing cited references for BIOSIS Previews content:
– Cited references for BIOSIS unique items (beginning with 2006 production year data)
– Cited references for BIOSIS items that overlap with items in the Web of Science (for all years, 1900 - forward)
– All citation data is contained within the BIOSIS database
Unique BIOSIS times-cited count
Available only on the Web of Knowledge platform
BIOSIS Citation Index• BIOSIS database has been known for decades for
extensive coverage of biomedicine: • Journals and Serials-over 5,000 titles
• Meetings, Conference
• Reviews of books, software
• Books, book chapters
• U.S. patents
• And unique, in-depth indexing:
14
Major Concepts Concept Code(s)
Taxonomic Data Disease Data
Chemical Data Gene Name Data
Sequence Data Geographic Data
Geologic Time Data Methods and Equipment Data
Parts & Structure Data Miscellaneous Descriptors
…Combined with the power of citation indexing in BIOSIS Citation Index
15
As with Web of Science, BIOSIS Citation Index includes a true cited reference index revealing exactly what has been cited, and allowing one to browse and select the exact cited items on which to search.
Explore citation relationships in BIOSIS Citation Index
17
This book chapter was cited 24 times within BIOSIS Citation Index
This book chapter was cited 31 times across Web of Knowledge
Use citation report visualization
19
Personalized medicine: concept code= psychiatry-addiction alcohol, drugs, smoking
Precise searching for relevant biomedical research
• Chemical=gramicidin S
• Major concept=(Pharmaceuticals)
• Concept Code=(Blood - Blood and lymph studies)
• Taxonomic data=(Hominidae)
• Literature Type=(Meeting Paper) 20
Research Analytics: tools like InCites provide comprehensive citation metrics and analytics
1.31
• InCites is a web-based research evaluation tool designed to track trends on the field, country, and institution level, and to enable detailed bibliometric analysis of the set of papers important to you.
Types of citation metrics and what they measure
22
Productivity # papers
Total influence
# citations
H-index
Efficiency
Avg. citation rate
Percent of papers cited
Relative Impact/Benchmarking
Journal actual/expected citation rate
Category actual/ expected citation rate
Percentile in category and mean percentile
% papers in top 10% of their field
% papers in top 1% of their field
Aggregated Performance Indicator
Specialization Disciplinarity indexInterdisciplinarity index
Can be applied to an institution, a researcher, a research group, etc.
Personalized medicine: trend in publications and citations
23
70-fold increase in papers using this terminology over the 30 year period
Citations increased from 723 in 1990 to 57,127 in 2009
pa
pe
rs
cita
tion
s
Research Analytics: metrics from InCites
Most highly-cited paper in personalized medicine:
• vant Veer LJ, Dai HY, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature (415), 6871. 530-536. Jan 31, 2002.
24
Citation metrics
Times Cited: 2,784
Journal performance ratio: 16.06 (cited over 16 times the expected rate for the journal)
Category performance ratio: 24.96 (cited almost 25 times the expected rate for the field of oncology)
Percentile: Top 0.005% of oncology papers from 2002
Highly Cited Institutions: Personalized medicine
25
# citations received
Mayo Clinic & Mayo Foundation 10,350
Harvard University 10,251
National Cancer Institute 7,928
University of Washington 7,236
University of California San Francisco 6,917
Source: Web of Science and InCites
Coauthored Papers Country Country
210Canada USA
179England USA
160Germany USA
122Italy USA
112Netherlands USA
77Germany Netherlands
77Peoples R China USA
74England Germany
74Germany Switzerland
72France USA
69Australia USA
68Japan USA
64Spain USA
CoauthoredPapers Country Country
210Canada USA
179England USA
160Germany USA
122Italy USA
112Netherlands USA
77Germany Netherlands
77Peoples R China USA
74England Germany
74Germany Switzerland
72France USA
69Australia USA
68Japan USA
64Spain USA
Coauthored Papers Country Country
83Canada USA
74Germany USA
73England USA
47Italy USA
34England Germany
34France USA
30France Germany
29Switzerland USA
28Netherlands USA
25England France
24Australia USA
24England Italy
24Japan USA
Changing collaboration partners
Coauthored Papers Country Country
83Canada USA
74Germany USA
73England USA
47Italy USA
34England Germany
34France USA
30France Germany
29Switzerland USA
28Netherlands USA
25England France
24Australia USA
24England Italy
24Japan USA
2000-2004 2005-2009
Drill down to Merck papers
29
What topics is Merck researching? Which are highly cited?
# citations keyword
264SURROGATE END-POINTS
231BREAST-CANCER
187ASSOCIATION
174CARDIOVASCULAR-DISEASE
174CORONARY-HEART-DISEASE
173ALZHEIMERS-DISEASE
173B-CELL LYMPHOMA
173C-REACTIVE PROTEIN
173IN-VIVO
173MILD COGNITIVE IMPAIRMENT
173POSITRON-EMISSION-TOMOGRAPHY
168GENE-EXPRESSION PROFILES
With whom is Merck collaborating?
http://mayoresearch.mayo.edu/mayo/research/staff/weinshilboum_rm.cfm
Most highly cited author in this topical dataset
30
Richard M. Weinshilboum, M.D. Mayo Clinic
http://mayoresearch.mayo.edu/mayo/research/staff/weinshilboum_rm.cfm
31
Dr. Weinshilboum’s most cited paper
Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. Vol 6. 1996. (Article)
Journal Expected citations: 61.78
Average citations specific to journal, year of article, and document type.Baseline for journal performance.Weinshilboum’s ratio of actual cites to expected: 9.27 (573/61.78)
Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. Vol 6. 1996. (Article) Times cited: 573
32
Dr. Weinshilboum’s most cited paper
Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. Vol 6. 1996. (Article)
Category Expected citations: 23.31
Average citations specific to category, year of article, and document type.Baseline for category performance.Weinshilboum’s ratio of actual cites to expected: 23.04 (537/23.31)
Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. Vol 6. 1996. (Article) Times cited: 573
Category : pharmacology and pharmacy
33
Dr. Weinshilboum’s most cited paper
Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. Vol 6. 1996. (Article)
Percentile: 0.028%
Percentile position specific to field and year. The closer to zero, the more highly cited.
Weinshilboum’s paper falls into the top 0.028% of all pharmacology/pharmacy papers from 1996.
Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. Vol 6. 1996. (Article) Times cited: 573
Category : pharmacology and pharmacy
34
Dr. Weinshilboum’s most cited paper
Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. Vol 6. 1996. (Article)
Times cited: 573
Weinshilboum, RM-summary metrics
35
Relative Impact/Bench-marking
Journal actual/expected
1.49
Category actual/expected
2.48
Mean percentile 27.34
% papers in top 10% of their field
37%
% papers in top 1% of their field
8%
Special-ization
Disciplinarity index 0.22
Productivity # papers 112
Total influence
# citations 4,086
H-index 33
Efficiency Avg. citation rate
36.48
Percent of papers cited
81.25
Weinshilboum’s papers perform 49% above their journals’ normal citation rates and 148% above their categories’ normal citation rates. His papers rank in the top 27% of their fields, according to citation count.